NEW YORK, Dec. 30 - Belgian biotech services provider Eurogentec will acquire WITA Proteomics, the companies said recently.
Terms of the acquisition were not immediately known, and officials from either company were unavailable for comment until after the New Year, according to calls placed to their offices this morning.
WITA Proteomics, headquarter in Berlin, offers biotech customers 2D gel electrophoresis, mass spectrometry-based protein identification, and sequencing services. Eurogentec said in a press release on Dec. 19 that these services will "complement ideally" its own proteomics efforts.
"In conjunction with our new protein array platform, WITA Proteomics technology will enable us to propose an integrated solution to our customers," Eurogentec said in the release.
Eurogentec, which employs 260 people, supplies a wide range of biotech tools and services to the biopharmaceutical industry and academic labs. The company was founded in 1985 as a spin-off of the University of Liège.
Headquartered in the Sart Tilman Science Park in Liège, Eurogentec has subsidiaries in France, Germany, the UK, the Netherlands and a branch office in Switzerland.
It was not clear how many people are currently employed at WITA Proteomics, or what their future is as part of Eurogentec. Also not immediately known is the way the acquisition might affect the collaborations WITA has struck since the company was founded two years ago.
As GenomeWeb reported last year, WITA agreed to provide services for Nestle and, separately, to collaborate with Pharmagene toprovide a full service drug discovery and validation service for pharmaceutical and biotechnology customers.